A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Servier
OHSU Knight Cancer Institute
GSO Global Clinical Research BV
AstraZeneca
Massachusetts General Hospital
mAbxience Research S.L.
University Health Network, Toronto
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Pittsburgh
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Center, Korea